10 Results for "

LRRK2G2019S

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "LRRK2G2019S" in MCE Product Catalog:

  • Targets Recommended:
8
8 Cited Publications
Cat. No.: HY-10875
CAS No.: 1234480-84-2
Purity:  99.42%
Target:  

LRRK2 Apoptosis

Research Areas:  

Neurological Disease Cancer

LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13488
CAS No.: 1351758-81-0
Purity:  99.55%
Target:  

LRRK2 MNK

Research Areas:  

Neurological Disease

HG-10-102-01 is a highly potent, selective, and brain-penetrable LRRK2 inhibitor, with IC50 values of 20.3 and 3.2 nM against wild-type LRRK2 and LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2 and MLK1, with IC50 values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research .
loading...
    loading...
Cat. No.: HY-14403
CAS No.: 1234479-76-5
Purity:  99.55%
Target:  

ERK

Research Areas:  

Cancer

ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
loading...
    loading...
Cat. No.: HY-16936
CAS No.: 1700693-08-8
Target:  

LRRK2

Research Areas:  

Neurological Disease

JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .
loading...
    loading...
Cat. No.: HY-P10636
CAS No.: 1159973-22-4
Target:  

LRRK2

Research Areas:  

Others

Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .
loading...
    loading...
Cat. No.: HY-158365
CAS No.: 2942328-06-3
Target:  

LRRK2

Research Areas:  

Neurological Disease

LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC50 of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC50=22 μM). LRRK2-IN-14 has blood-brain barrier permeability .
loading...
    loading...
Cat. No.: HY-10875R
CAS No.: 1234480-84-2
LRRK2-IN-1 (Standard) is the analytical standard of LRRK2-IN-1 (HY-10875). This product is intended for research and analytical applications. LRRK2-IN-1 is a potent and selective LRRK2 inhibitor with IC50 of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.
loading...
    loading...
Cat. No.: HY-184198
CAS No.: 1427947-55-4
Research Areas:  

Neurological Disease

LRRK2-IN-22 is a LRRK2 inhibitor, with IC50 values of 315.7 nM and 255.4 nM against LRRK2 WT and LRRK2 G2019S, respectively. LRRK2-IN-22 effectively inhibits LRRK2 kinase activity and downstream Rab10 phosphorylation, reduces ROS, and exhibits low cytotoxicity. LRRK2-IN-22 can be used for research on Parkinson's disease .
loading...
    loading...
Cat. No.: HY-180320
CAS No.: 1632368-13-8
Target:  

LRRK2

Research Areas:  

Neurological Disease

Lu AF58786 is a potent and selective LRRK2 inhibitor with an IC50 of 12 nM. Lu AF58786 also exhibits inhibition activity against LRRK2 G2019S and LRRK2 A2016T with IC50s of 19 and 93 nM. Lu AF58786 inhibits phosphorylation of LRRK2, Rab10 and Rab12 in human peripheral blood mononuclear cells. Lu AF58786 can be used for parkinson’s disease research .
loading...
    loading...
Cat. No.: HY-184652
Target:  

LRRK2 JNK CaMK Casein Kinase

Research Areas:  

Neurological Disease

LRRK2/JNK3-IN-1 is a brain-penetrant multi-target inhibitor of LRRK2 (including G2019S mutant and wild-type) and JNK3, with enzymatic IC50 values of 3.90 nM against LRRK2 G2019S, 3.24 nM against wild-type LRRK2, and 22.1 nM against JNK3. LRRK2/JNK3-IN-1 displays favorable selectivity in a 97-kinase profiling screen, and also shows inhibitory activity against JNK1, JNK2, and MKNK2. LRRK2/JNK3-IN-1 can be used for the research of Parkinson's disease .
loading...
    loading...